Centogene, a rare disease-focused company, has become a key player in the healthcare industry by transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies on a global scale. Through the Pharmaceutical, Diagnostics, and COVID-19 testing segments, the company has developed a data and biological repository called the Rare Disease Platform. The platform comprises epidemiologic, phenotypic, and heterogenetic data that improve identifying and monitoring rare diseases while providing solutions that expedite orphan drug development. The company offers various services such as target discovery, patient recruitment, epidemiological insights, and genetic sequencing and diagnostics services to healthcare professionals worldwide. Moreover, Centogene provides COVID-19 testing solutions, including PCR and antigen testing services. The company has recently inked collaboration and license agreements with renowned pharmaceutical companies such as Pfizer and Takeda. Established in 2006, Centogene is based in Rostock, Germany, and has become a leading global health solutions provider.
Centogene N.V.'s ticker is CNTG
The company's shares trade on the NASDAQ stock exchange
They are based in Rostock, Germany
There are 201-500 employees working at Centogene N.V.
It is https://www.centogene.com/
Centogene N.V. is in the Healthcare sector
Centogene N.V. is in the Diagnostic Substances industry
The following five companies are Centogene N.V.'s industry peers: